ProteqFlu

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI05AD02

INN (International Name):

Equine influenza vaccine (live recombinant)

Therapeutic group:

Cavalli

Therapeutic area:

Prodotti immunologici, Live virali vaccini contro il virus dell'influenza equina

Therapeutic indications:

Immunizzazione attiva di cavalli di età pari o superiore a quattro mesi contro l'influenza equina per ridurre i segni clinici e l'escrezione di virus dopo l'infezione.

Product summary:

Revision: 14

Authorization status:

autorizzato

Authorization date:

2003-03-06

Patient Information leaflet

                                13
B. FOGLIETTO ILLUSTRATIVO
14
FOGLIETTO ILLUSTRATIVO
PROTEQFLU SOSPENSIONE INIETTABILE PER CAVALLI
1.
NOME E INDIRIZZO DEL TITOLARE DELL'AUTORIZZAZIONE
ALL'IMMISSIONE IN COMMERCIO E DEL TITOLARE DELL’AUTORIZZAZIONE
ALLA PRODUZIONE RESPONSABILE DEL RILASCIO DEI LOTTI DI
FABBRICAZIONE, SE DIVERSI
Titolare dell’autorizzazione all’immissione in commercio:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANIA
Produttore responsabile del rilascio dei lotti di fabbricazione:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
F-69800 Saint Priest
FRANCIA
2.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
ProteqFlu sospensione iniettabile per cavalli
3.
INDICAZIONE DEL(I) PRINCIPIO(I) ATTIVO(I) E DEGLI ALTRI INGREDIENTI
Una dose da 1 ml contiene:
PRINCIPI ATTIVI:
Virus del vaiolo del canarino (vCP2242), ricombinante per influenza
A/eq/Ohio/03 [H
3
N
8
]
..................................................................................................................................
> 5,3 log10 FAID
50
*
Virus del vaiolo del canarino ( vCP3011), ricombinante per influenza
A/eq/Richmond/1/07 [H
3
N
8
]
..................................................................................................................................
> 5,3 log10 FAID
50
*
*contenuto in vCP determinato attraverso FAID
50
globale (dose infettante 50% determinata mediante
immunofluorescenza) e rapporto tra vCP attraverso qPCR.
ADIUVANTE:
Carbomero
..........................................................................................................................................
4 mg
4.
INDICAZIONE(I)
Immunizzazione attiva dei cavalli di 4 mesi, o più, di età nei
confronti dell’influenza equina per
ridurre i sintomi clinici e l’escrezione dei virus in seguito ad
infezione.
Instaurarsi dell’immunità: 14 giorni dopo la vaccinazione di base.
Durata dell’immunità indotta dallo schema vaccinale: 5 mesi dopo la
vaccinazione di base e 1 anno
dopo la terza vaccinazione.
5.
CONTROINDI
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ALLEGATO I
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
2
1.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
ProteqFlu sospensione iniettabile per cavalli
2.
COMPOSIZIONE QUALITATIVA E QUANTITATIVA
Una dose da 1 ml contiene:
PRINCIPI ATTIVI:
Virus del vaiolo del canarino (vCP2242), ricombinante per influenza
A/eq/Ohio/03 [H
3
N
8
]
...................................................................................................................................
≥
5,3 log10 FAID
50
*
Virus del vaiolo del canarino (vCP3011), ricombinante per influenza
A/eq/ Richmond/1/07 [H
3
N
8
]
...................................................................................................................................
≥
5,3 log10 FAID
50
*
*contenuto in vCP determinato attraverso FAID
50
globale (dose infettante 50% determinata mediante
immunofluorescenza) e rapporto tra vCP attraverso qPCR.
ADIUVANTE:
Carbomero
.......................................................................................................................................
4 mg.
Per l’elenco completo degli eccipienti, vedere paragrafo 6.1.
3.
FORMA FARMACEUTICA
Sospensione iniettabile.
4.
INFORMAZIONI CLINICHE
4.1
SPECIE DI DESTINAZIONE
Cavalli
4.2
INDICAZIONI PER L’UTILIZZAZIONE, SPECIFICANDO LE SPECIE DI
DESTINAZIONE
Immunizzazione attiva dei cavalli di 4 mesi, o più, di età nei
confronti dell’influenza equina per
ridurre i sintomi clinici e l’escrezione dei virus in seguito ad
infezione.
Instaurarsi dell’immunità: 14 giorni dopo la vaccinazione di base.
Durata dell’immunità indotta dallo schema vaccinale: 5 mesi dopo la
vaccinazione di base e 1 anno
dopo la terza vaccinazione.
4.3
CONTROINDICAZIONI
Nessuna.
4.4
AVVERTENZE SPECIALI
Nessuna.
4.5
PRECAUZIONI SPECIALI PER L’IMPIEGO
Precauzioni speciali per l’impiego negli animali
Devono essere vaccinati solo gli animali sani.
3
Precauzioni speciali che devono essere adottate dalla persona che
somministra il medicinale
veterinario agli animali
In caso di auto-iniezione accidentale, 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-11-2020
Public Assessment Report Public Assessment Report Bulgarian 17-10-2014
Patient Information leaflet Patient Information leaflet Spanish 23-11-2020
Public Assessment Report Public Assessment Report Spanish 17-10-2014
Patient Information leaflet Patient Information leaflet Czech 23-11-2020
Public Assessment Report Public Assessment Report Czech 17-10-2014
Patient Information leaflet Patient Information leaflet Danish 23-11-2020
Public Assessment Report Public Assessment Report Danish 17-10-2014
Patient Information leaflet Patient Information leaflet German 23-11-2020
Public Assessment Report Public Assessment Report German 17-10-2014
Patient Information leaflet Patient Information leaflet Estonian 23-11-2020
Public Assessment Report Public Assessment Report Estonian 17-10-2014
Patient Information leaflet Patient Information leaflet Greek 23-11-2020
Public Assessment Report Public Assessment Report Greek 17-10-2014
Patient Information leaflet Patient Information leaflet English 23-11-2020
Public Assessment Report Public Assessment Report English 17-10-2014
Patient Information leaflet Patient Information leaflet French 23-11-2020
Public Assessment Report Public Assessment Report French 17-10-2014
Patient Information leaflet Patient Information leaflet Latvian 23-11-2020
Public Assessment Report Public Assessment Report Latvian 17-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-11-2020
Public Assessment Report Public Assessment Report Lithuanian 17-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 23-11-2020
Public Assessment Report Public Assessment Report Hungarian 17-10-2014
Patient Information leaflet Patient Information leaflet Maltese 23-11-2020
Public Assessment Report Public Assessment Report Maltese 17-10-2014
Patient Information leaflet Patient Information leaflet Dutch 23-11-2020
Public Assessment Report Public Assessment Report Dutch 17-10-2014
Patient Information leaflet Patient Information leaflet Polish 23-11-2020
Public Assessment Report Public Assessment Report Polish 17-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 23-11-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 23-11-2020
Public Assessment Report Public Assessment Report Portuguese 17-10-2014
Patient Information leaflet Patient Information leaflet Romanian 23-11-2020
Public Assessment Report Public Assessment Report Romanian 17-10-2014
Patient Information leaflet Patient Information leaflet Slovak 23-11-2020
Public Assessment Report Public Assessment Report Slovak 17-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 23-11-2020
Public Assessment Report Public Assessment Report Slovenian 17-10-2014
Patient Information leaflet Patient Information leaflet Finnish 23-11-2020
Public Assessment Report Public Assessment Report Finnish 17-10-2014
Patient Information leaflet Patient Information leaflet Swedish 23-11-2020
Public Assessment Report Public Assessment Report Swedish 17-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 23-11-2020
Patient Information leaflet Patient Information leaflet Icelandic 23-11-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 23-11-2020
Patient Information leaflet Patient Information leaflet Croatian 23-11-2020
Public Assessment Report Public Assessment Report Croatian 17-10-2014

View documents history